2022 Joint Annual Meeting ISMRM-ESMRMB

2022 Call for Abstracts — Closed

Deadline for Stipend Application & Membership Application/Dues Payment:
10 November 2021 at 23:59 EST

The Annual Meeting Program Committee (AMPC) invites abstract submissions for presentation at the hybrid 2022 Joint Annual Meeting ISMRM-ESMRMB, 07-12 May 2022 in London, England, UK. Submissions must contain new, previously unpublished material. All abstracts must be submitted electronically via the ISMRM Website.

In line with the policy announced by the ISMRM president in 2021 (The Future is Hybrid), the annual meeting in 2022 will be hybrid.  For scientific abstracts, this means that we are offering both “In-person” (on-site) and “Online” presentation options. While some of the detail are still under development, our guiding principles are that all participants in the Annual Meeting should be able to connect with each other, and that the in-person experience is not compromised by the hybrid format. The aim is to democratize access to our community and to allow all of our members to present and discuss the latest research, including those who are not able to travel.

When submitting, authors will select whether they will present in person in London, or whether they will require an online presentation. Presenters of an in-person abstract will be offered the opportunity to convert to an online presentation closer to the date in the event that they are still subject to travel restrictions. Abstracts that are submitted with the online presentation option will not be converted to in-person at a later date.

As usual, during the abstract submission process, you will be given the opportunity to select your preferred presentation format. Specifically, abstracts can be submitted for presentation in an oral session or a poster session. The AMPC will do their best to accommodate your preferences.

Detailed design and presentation guidelines will be available on this website in February after acceptance notices have been emailed.

SUBMISSION GUIDELINES

Rejection of Duplicate Abstracts
Any abstract(s) deemed to duplicate or to contain significant overlap of content will be rejected. Determination of what constitutes duplication, including abstracts submitted in multiple categories or over multiple years, is at the discretion of the AMPC. Details of identified duplicate submissions will be maintained in our database and may jeopardize submission of future abstracts by the same individuals or institutions. The electronic submission system facilitates easy identification of duplicate text and data.

Failure to Present
All accepted works that are not withdrawn before the 28 February 2021 withdrawal deadline must be presented by the author or their designee. A database of late cancellations and no-shows is maintained, and consistent infractions may jeopardize submission of future abstracts by the same individuals or institutions.

Synopsis
Each abstract is accompanied by a 100-word synopsis for inclusion in the online program. It should include a brief summary of the problem, methods, results, and conclusions. The synopsis must include text only, without equations or images, and be without references or citations to items described in the full abstract. The synopsis text should NOT be duplicated in the actual abstract.

Summary of Main Findings
A 250-character summary of the abstract’s main findings is requested for generation of digital poster previews. It is expected that this content will overlap with the 100-word synopsis. As with the synopsis, summary must include text only, without equations or images, and be without references or citations to items described in the full abstract.

Digital Poster “Teaser” Previews
Presentations will be highlighted using a single figure and information about the authors in an abstract thumbnail. In order to accomplish this, you will be asked for the following:

  1. A choice of a secondary figure (in addition to the primary figure already required)
  2. A “Summary of Main Findings” (mini-synopsis)
  3. An institutional logo image file. If you need to acknowledge more than one institution, you must create a single image containing any necessary logos. Alternatively, you may use a project- or consortium logo instead of institutional logos.

Suggested Abstract Format
We recommend including the following sections, although we also note that there are often good reasons to deviate from this format. In each section, answer the question listed below (do not repeat the actual question in the body of your abstract).

  • INTRODUCTION: “Why was this study/research performed? What unsolved problem are you addressing?”
  • METHODS: “How did you study this problem?”
  • RESULTS: “Report the data, analyses and/or outcomes”
  • DISCUSSION: “How do you interpret the results?”
  • CONCLUSION: “What is the relevance to clinical practice or future research?”
  • REFERENCES: References should use the suggested style below.

Word Limits
The following word limits will apply:

  • Title: 125 characters
  • Synopsis: 100 words
  • Body of the Abstract: 850 words (references not included)
  • Summary of Main Findings: 250 Characters (~35 words)
  • Figures: up to 5 only
  • Figure Captions: 500 characters per caption

References
Cite each source in numerical order using superscript Arabic numerals (1, 2, 3…).

  • Example 1:
    A review of regulations has been complete by the WHO15.
  • Example 2:
    The data were as follows 3,4:
  • Example 3:
    …methods for MR fingerprinting 11-14,25,

At the end of the abstract, list references numerically in the order in which they were cited in the text.

  • Example 1:
    1. Rainier S, Thomas D, Tokarz D, et al. Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis. Arch Neurol. 2004;61(7):1025‐1029.
  • Example 2:
    2. World Health Organization. Injury: A Leading Cause of the Global Burden of Disease, 2000. Geneva, Switzerland: World Health Organization; 2002.
  • Example 3:
    3. Weiss R. The promise of precision prescriptions. Washington Post. June 24, 2000:A1. http://www.washingtonpost.com. Accessed October 10, 2001.

FURTHER INFORMATION

Abstract Content Guidelines

  • Bias: The content may not promote the proprietary interests of any commercial entity. Evident bias in favor of a particular product or company is grounds for rejection. (Reference to the use of a particular company’s products or equipment does not represent bias. Non-data-driven statements of superiority, however, would be considered biased.)
  • Content must be restricted to scientific, engineering, and clinical studies, as well as industry issues and operation of devices. Product/company names should be included only to identify the MR hardware/software/peripherals used but not to promote proprietary interests (see first bullet point).
  • All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for the recommendations as indications or contraindications in the care of patients.
  • All scientific research referred to, reported or used in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
  • Abstracts previously submitted to the ISMRM or to another society/journal, but were not accepted, may be resubmitted.

Abstract Review Criteria

  • Adherence to the Abstract Content Guidelines (as stated above).
  • Duplication of Content (see also above). Multiple submissions of the same or nearly the same abstract is grounds for rejection of all submitted abstracts.
  • Innovation/novelty: advancement of knowledge, and/or improvement of capabilities.
  • Quality: The results should be substantive and not just implied. Where appropriate:
    • Comprehensive statistical analysis should be applied.
    • Images and spectra should be of the highest quality.
  • Impact: The method or data in the abstract should aim to advance or change the field in significant ways. Incremental changes are less likely to be accepted for presentation.

Tips for Authors

  • Start your submission early. You can complete the online forms, compose your abstract and then upload it at any time before the deadline. We recommend that you complete the online forms EARLY, even if your abstract is not yet complete. This will greatly reduce the load on the abstract system, improving speed of access as the deadline approaches.
  • Consider your submission labels carefully. Abstract reviewers are assigned based on the chosen labels. It is therefore critical that you select these label carefully, as reviewers who are not expert in your topic may not be able to assess its quality appropriately. The labels will also be used to assign accepted abstracts to sessions on the meeting.
  • Contact all co-authors prior to submission. It is considered unethical to submit abstracts listing co-authors who have not agreed to the submission. In general, co-authors will expect to read and approve of the content of an abstract, but at a minimum they should be aware of the submission and consented to being listed as an author.

Publication of Abstracts

The Proceedings will be published electronically only. The full text of all accepted abstracts will be available online two weeks before the meeting to pre-registered attendees only (23 April 2022). If you wish to have access to the Proceedings before the meeting, you must pre-register.

All submitted abstracts are treated as confidential from the time of submission to the publication date of 23 April 2022.

All copyrights to accepted abstracts become the property of ISMRM. No proprietary information may be withheld by authors.

Be sure to read “How to Submit Your HTML-Based Abstract” for further details and important formatting requirements!

Frequently Asked Questions

What does it mean to select “In-Person (On-Site) as a meeting presentation format?

Authors should select “In-Person” if they have the firm intention of travelling to London. Presenters of an in-person abstract will be offered the opportunity to convert to an online presentation in the event that they are still subject to travel restrictions closer to the date. Absent a notification from the ISMRM, the abstract should be presented in London as either an oral, power-pitch or e-poster as communicated in the acceptance mail.

What does it mean to select “Online” as a meeting presentation preference?

Authors should select “Online” if they have no intention of travelling to London but are still keen to present their recent research to the entire community. While these presentations cannot be converted to on-site presentations at a later stage, any authors that select and present online are welcome with open arms in London should they later decide to travel to the Annual Meeting. While the specific format of online presentations is still being developed, our aim is to create maximal opportunities for effective discussion and exchange between attendees.

How should I pick my labels? How important is the primary label?

The choice of labels, and especially the primary label, is critical and should be considered carefully. The labels will be used in 4 different ways: (1) to select reviewers for the abstract, (2) to determine the type of session they will be presented in if accepted, (3) to search for abstracts during the meeting, and (4) to search for abstracts after the meeting in the ISMRM archives and proceedings.

As a guidance in selecting labels, think of the primary label as the heading of the session where you would like to present your abstract. As an example, let’s say you have an abstract on “Cardiac DTI in a mouse model of myocardial ischemia.” Do you want this to be presented in a session about the “Heart”? In a session about “Ischemia”? In a session about “Diffusion Tensor Imaging”? Or in a session about “Preclinical” MRI? With the choice of primary label, you indicate your preference to the AMPC. The selection of reviewers will follow the same logic. For instance, if you have selected “Diffusion Tensor Imaging” as primary label, your abstract will be reviewed by an expert in Diffusion Tensor Imaging who may, however, be less familiar with mouse models, ischemia, preclinical MRI, or cardiac MRI.

The secondary label is also important as it will be used to subdivide primary labels that attract many submissions; conversely, when the primary label attracts too few submissions the abstract may be allocated based on the secondary label instead.

The third and fourth labels will not be used for assigning reviewers or creating sessions, but they will enable attendees to more easily find your abstract during the meeting. In the example above, an attendee will find your abstract after filtering the program with the labels “Heart,” “Diffusion Tensor Imaging,” “Preclinical,” “Ischemia.”

The abstract submission site is now closed.